Shmuel A Ben-Sasson

This inventor holds 22 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Biomedical Innovations. Top assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Children's Medical Center Corporation, Raziel Therapeutics Ltd. Active years: 1988-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shmuel A Ben-Sasson. Retrieved from https://idiyas.com/inventor/shmuel-a-ben-sasson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 9)

% Patents Active = 59.1

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 1.2

ph-index = 6

Forward Citations = 136(Granted Patents)

Company Filing History:

6 out of 915

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

3 out of 1,074

Children's Medical Center Corporation

patents

3 out of 3

Raziel Therapeutics Ltd

Rafa Laboratories Ltd.

Yissum Research and Development

patents

8. 5 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2026

Loading Chart...

Areas of Expertise:

Glyceryltriacetate

Carbazole Derivatives

IGF-1R Inhibitors

Pro-Angiogenic Peptides

Biological Barrier Penetration

Anti-Cancer Therapy

Short Peptides

Multivalent Ligands

Tissue Remodeling

Protein Kinases

G-Protein-Coupled Receptors

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758520 - Glyceryltriacetate (GTA) for use in improving breathing (2026-10-13),

2. 12097179 - Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof (2024-09-24),

3. 11191748 - Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof (2021-12-07),

4. 10632102 - Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof (2020-04-28),

5. 10188659 - IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases (2019-01-29),

6. 9873724 - Pro-angiogenic peptides and peptide conjugates (2018-01-23),

7. 9770454 - IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases (2017-09-26),

8. 9447040 - Tricyclic compounds, compositions comprising them and uses thereof (2016-09-20),

9. 8241670 - Compositions capable of facilitating penetration across a biological barrier (2012-08-14),

10. 7838513 - Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent (2010-11-23),

11. 7683031 - [object Object] (2010-03-23),

12. 7115707 - Amino acid sequences capable of facilitating penetration across a biological barrier (2006-10-03),

13. 7037891 - Methods of modulating G-protein-coupled receptor kinase-associated signal transduction (2006-05-02),

14. 6833436 - Short peptides which selectively modulate the activity of serine/threonine kinases (2004-12-21),

15. 6770626 - Tissue remodeling (2004-08-03),

Title: Shmuel A Ben-Sasson: Innovator in Fibrotic Disease Treatment

Introduction: Shmuel A Ben-Sasson is a prominent inventor based in Jerusalem, Israel, known for his substantial contributions to the field of medical innovations. With an impressive portfolio of 21 patents, he has dedicated his research to developing therapies for fibrotic diseases, aiming to improve the quality of life for countless individuals suffering from these conditions.

Latest Patents: Among Ben-Sasson's latest inventions are groundbreaking carbazole derivatives that target the treatment of fibrotic diseases. These derivatives address pathological collagen deposition in various tissues and organs, aiming to alleviate related symptoms and conditions. His dedicated research in this area has been instrumental in advancing treatment options for afflictions associated with fibrosis.

Career Highlights: Ben-Sasson's career is characterized by a strong focus on medical research and innovation. His work has garnered attention within the scientific community and has contributed to the understanding and treatment of fibrotic diseases. His efforts have not only advanced his career but have also paved the way for new methodologies in disease management.

Collaborations: Throughout his career, Shmuel A Ben-Sasson has collaborated with esteemed colleagues such as Hadas Reuveni and Ehud Cohen. These partnerships have further enriched his research endeavors and fostered innovation in the development of therapies for fibrotic diseases.

Conclusion: Shmuel A Ben-Sasson continues to be a driving force in the medical innovation landscape, particularly in the realm of fibrotic disease treatment. His contributions not only enhance our understanding of these conditions but also offer hope for effective therapeutic solutions. As he pursues further advancements, the impact of his work will undoubtedly resonate within the scientific community and beyond.

Profile summary based on public USPTO records.